<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162563</url>
  </required_header>
  <id_info>
    <org_study_id>CAIRO5</org_study_id>
    <secondary_id>2013-005435-24</secondary_id>
    <nct_id>NCT02162563</nct_id>
  </id_info>
  <brief_title>Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases</brief_title>
  <acronym>CAIRO5</acronym>
  <official_title>Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer patients with initially unresectable liver-only metastases may be cured
      after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal
      neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for
      resectability.

      In this study colorectal cancer patients with initially unresectable liver-only metastases,
      as prospectively confirmed by an expert panel according to predefined criteria, will be
      tested for RAS and BRAF tumor mutation status and selected by location of primary tumor.
      Patients with RAS or BRAF mutant and/or right sided tumors will be randomised between doublet
      chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab (schedule 1), and triple chemotherapy
      (FOLFOXIRI) plus bevacizumab (schedule 2). Patients with RAS AND BRAF wildtype AND left-sided
      primary tumors will be randomized between doublet chemotherapy (FOLFOX or FOLFIRI) plus
      either bevacizumab (schedule 1) or panitumumab (schedule 3). Patient imaging will be reviewed
      for resectability by a central panel, consisting of at least one radiologist and three
      surgeons every assessment. Central panel review will be performed prior to randomization as
      well as during treatment, as described in the protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified for resectability of liver metastases (potentially resectable
      versus permanently unresectable), serum lactate dehydrogenase (LDH) (normal versus abnormal),
      BRAF mutation status (wildtype versus mutated), type of neoadjuvant chemotherapy (FOLFIRI
      versus FOLFOX) and hospital of registration.

      Patients with RAS and BRAF wildtype and left-sided primary tumors will be randomised between
      FOLFOX or FOLFIRI plus either bevacizumab or panitumumab. The choice between FOLFOX or
      FOLFIRI is to the discretion of the local investigator, however, the treatment is restricted
      to regimens that are specified in the protocol. Patients with RAS or BRAF mutated and/or
      right-sided primary tumors will be randomized between FOLFOX/ FOLFIRI (investigator choice)
      plus bevacizumab or 5FU, irinotecan, oxaliplatin (FOLFOXIRI) plus bevacizumab.

      Patients will be evaluated every 8 weeks by CT scan for disease status. The assigned systemic
      treatment should be continued for at least 6 months or earlier in case of resectability,
      progression of disease, unacceptable toxicity, or patient refusal. If after 6 months the
      panel concludes that the patient is still not resectable, it is highly unlikely that
      resectability will be achieved at all. Therefore the chemotherapy regimen may be reconsidered
      after 6 months of treatment. These patients should continue with the targeted drug in
      combination with chemotherapy, but the chemotherapy may be altered into a less toxic schedule
      such as fluoropyrimidine monotherapy. The targeted drug should be continued until progression
      or unacceptable toxicity. In patients who will become resectable and undergo secondary
      surgery of liver metastases, the total duration of preoperative and postoperative treatment
      together should be 6 months, with the chemotherapy schedule being administered according to
      the assigned treatment arm. However in these patients the targeted drug (bevacizumab or
      panitumumab) should not be continued after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Time from registration until progression or death whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/1 secondary resection rate</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>R0/1 secondary resection rate in each of the 4 study arms upon neoadjuvant treatment with chemotherapy plus targeted therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>8 years after last patient in study</time_frame>
    <description>From date of randomisation to death or last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (AE)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Patients will be evaluated for Adverse Events at the start of each treatment cycle according to CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>Pathological complete response rate (pCR) of the resected lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>After surgery during two months</time_frame>
    <description>Patients will be evaluated for surgical morbidity during 2 months. Postoperative morbidity will be scored according 'Clavien Dindo Grade'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of evaluation by the panel with outcome</measure>
    <time_frame>2 years after last patient in study</time_frame>
    <description>CT-scans will be reviewed for liver resectability by expert panel before randomisation and during neo-adjuvant treatment (every 8 weeks).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Arm B: FOLFOXIRI &amp; bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.
Intervention: FOLFOXIRI with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: FOLFOX/FOLFIRI &amp; bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
Intervention: FOLFOX/FOLFIRI with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: FOLFOX/FOLFIRI &amp; panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.
Intervention: FOLFOX/FOLFIRI with panitumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: FOLFOX/ FOLFIRI &amp; bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
Intervention: FOLFOX/FOLFIRI with bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/ FOLFIRI with bevacizumab</intervention_name>
    <description>FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm A: FOLFOX/FOLFIRI &amp; bevacizumab</arm_group_label>
    <arm_group_label>Arm C: FOLFOX/ FOLFIRI &amp; bevacizumab</arm_group_label>
    <other_name>- bevacizumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
    <other_name>- oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI with bevacizumab</intervention_name>
    <description>FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm B: FOLFOXIRI &amp; bevacizumab</arm_group_label>
    <other_name>- bevacizumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- oxaliplatin</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/ FOLFIRI with panitumumab</intervention_name>
    <description>FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks</description>
    <arm_group_label>Arm D: FOLFOX/FOLFIRI &amp; panitumumab</arm_group_label>
    <other_name>- panitumumab</other_name>
    <other_name>- irinotecan</other_name>
    <other_name>- leucovorin</other_name>
    <other_name>- 5-fluorouracil</other_name>
    <other_name>- oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal cancer

          -  Unresectable metastases confined to the liver according to CT scan, obtained ≤ 2 weeks
             prior to registration. Unresectability will be confirmed by the panel. Patients with
             small (≤ 1 cm) extrahepatic lesions that are not clearly suspicious of metastases are
             eligible.

          -  Adequate tumor tissue available for assessment of RAS/BRAF mutation status

          -  WHO performance status 0-1 (Karnofsky performance status ≥ 70)

          -  Age ≥ 18 years

          -  No contraindications for liver surgery

          -  In case of primary tumor in situ: tumor should be resectable

          -  In case of resected primary tumor: adequate recovery from surgery

          -  Adequate organ functions, as determined by normal bone marrow function (Hb ³ 6.0
             mmol/L, absolute neutrophil count ³ 1.5 x 109/L, platelets ³ 100 x 109/L), renal
             function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft formula, ³ 30
             ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 5x ULN)

          -  Life expectancy &gt; 12 weeks

          -  Expected adequacy of follow-up

          -  Written informed consent

        Exclusion Criteria:

          -  Extrahepatic metastases, with the exception of small (≤ 1 cm) extrahepatic lesionsthat
             are not clearly suspicious of metastases

          -  Unresectable primary tumor

          -  Serious comorbidity or any other condition preventing the safe administration of study
             treatment (including both systemic treatment and surgery)

          -  Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive
             heart failure, CVA) within 12 months before registration

          -  Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3
             antihypertensive drugs

          -  Previous systemic treatment for metastatic disease; previous adjuvant treatment is
             allowed if completed ≥ 6 months prior to registration

          -  Previous surgery for metastatic disease

          -  Previous intolerance of study drugs in the adjuvant setting

          -  Pregnant or lactating women

          -  Second primary malignancy within the past 5 years with the exception of adequately
             treated in situ carcinoma of any organ or basal cell carcinoma of the skin

          -  Any concomitant experimental treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.J.A. Punt, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Amsterdam NL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T.M. van Gulik, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Amsterdam NL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>K. Bolhuis, Drs.</last_name>
    <phone>+31 20 5665568</phone>
    <email>k.bolhuis@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>B. Hemmes, PhD</last_name>
    <phone>+31 617806051</phone>
    <email>b.hemmes@iknl.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <state>Drenthe</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Nieboer, dr.</last_name>
      <email>p.nieboer@wza.nl</email>
    </contact>
    <investigator>
      <last_name>P. Nieboer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <state>Flevoland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.W. Sommeijer, dr.</last_name>
      <email>d.w.sommeijer@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>D.W. Sommeijer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Nij Smellinghe</name>
      <address>
        <city>Drachten</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Hovenga, dr.</last_name>
      <email>s.hovenga@nijsmellinghe.nl</email>
    </contact>
    <investigator>
      <last_name>S. Hovenga, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden, loc. Zuid</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.B. Polée, dr.</last_name>
      <email>m.polee@znb.nl</email>
    </contact>
    <investigator>
      <last_name>M.B. Polée, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Veldhuis, dr.</last_name>
      <email>g.veldhuis@antonius-sneek.nl</email>
    </contact>
    <investigator>
      <last_name>G.J. Veldhuis, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.M. Smit, dr.</last_name>
      <email>j.m.smit@gelre.nl</email>
    </contact>
    <investigator>
      <last_name>J.M. Smit, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Blaisse</last_name>
      <email>rblaisse@rijnstate.nl</email>
    </contact>
    <investigator>
      <last_name>R Blaisse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Haringhuizen</last_name>
      <email>haringhuizen@zgv.nl</email>
    </contact>
    <investigator>
      <last_name>A. Haringhuizen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Jansdal Ziekenhuis</name>
      <address>
        <city>Harderwijk</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Temizkan, dr.</last_name>
      <email>m.temizkan@stjansdal.nl</email>
    </contact>
    <investigator>
      <last_name>M. Temizkan, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. de Wilt, prof.dr.</last_name>
      <email>hans.dewilt@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>H. de Wilt, prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswijk</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.P. Schiphorst, dr.</last_name>
      <email>p.p.schiphorst@skbwinterswijk.nl</email>
    </contact>
    <investigator>
      <last_name>P.P. Schiphorst, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Center</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Warmerdam, dr.</last_name>
      <email>fwm01@atriummc.nl</email>
    </contact>
    <investigator>
      <last_name>F. Warmerdam, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.L.H. Jansen, dr.</last_name>
      <email>rob.jansen@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>R.L.H. Jansen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laurentius Ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.O. den Boer, dr.</last_name>
      <email>m.denboer@lzr.nl</email>
    </contact>
    <investigator>
      <last_name>M.O. den Boer, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Medical Center</name>
      <address>
        <city>Sittard - Geleen</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F.L.G. Erdkamp, dr.</last_name>
      <email>f.erdkamp@orbisconcern.nl</email>
    </contact>
    <investigator>
      <last_name>F.L.G. Erdkamp, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Vestjens, dr.</last_name>
      <email>hvestjens@viecuri.nl</email>
    </contact>
    <investigator>
      <last_name>H. Vestjens, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Gerhards</last_name>
      <email>m.f.gerhards@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>M Gerhards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Sinnige, dr.</last_name>
      <email>h.sinnige@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>H. Sinnige, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis</name>
      <address>
        <city>Bergen op Zoom</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Troost, dr.</last_name>
      <email>m.troost@bravis.nl</email>
    </contact>
    <investigator>
      <last_name>M Troost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O.J.L. Loosveld, dr</last_name>
      <email>o.loosveld@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>O.J.L. Loosveld, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. Creemers, dr.</last_name>
      <email>geert-jan.creemers@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>G.J. Creemers, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anna Ziekenhuis</name>
      <address>
        <city>Geldrop</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.E.M. Smals, dr.</last_name>
      <email>a.smals@st-anna.nl</email>
    </contact>
    <investigator>
      <last_name>A.E.M. Smals, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elkerliek Ziekenhuis</name>
      <address>
        <city>Helmond</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Vincent, drs.</last_name>
      <email>j.vincent@elkerliek.nl</email>
    </contact>
    <investigator>
      <last_name>J. Vincent, drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis Ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.J. Droogendijk, dr.</last_name>
      <email>hdroogendijk@fzr.nl</email>
    </contact>
    <investigator>
      <last_name>H.J. Droogendijk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.M.G.H. van Riel, dr.</last_name>
      <email>j.riel@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>J.M.G..H. van Riel, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. van Alphen</last_name>
      <email>rvalphen@tsz.nl</email>
    </contact>
    <investigator>
      <last_name>R. van Alphen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.H. Vos, dr.</last_name>
      <email>a.vos@bernhoven.nl</email>
    </contact>
    <investigator>
      <last_name>A.H. Vos, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum, loc. Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.M.H. Roumen, dr.</last_name>
      <email>r.roumen@mmc.nl</email>
    </contact>
    <investigator>
      <last_name>R.M.H. Roumen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.P. Hendriks, dr.</last_name>
      <email>m.p.hendriks@mca.nl</email>
    </contact>
    <investigator>
      <last_name>M.P. Hendriks, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.J.A. Punt, Prof. dr.</last_name>
      <phone>+31 20 5665955</phone>
      <email>c.punt@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>T.M. van Gulik, Prof. dr.</last_name>
      <phone>+31 20 5665570</phone>
      <email>t.m.vangulik@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>C.J.A. Punt, Prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.M. Ruers, prof. dr.</last_name>
      <email>t.ruers@nki.nl</email>
    </contact>
    <investigator>
      <last_name>T.M. Ruers, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BovenIJ Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.E. Dohmen, dr.</last_name>
      <email>s.dohmen@bovenij.nl</email>
    </contact>
    <investigator>
      <last_name>S.E. Dohmen, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.D. Kerver, Dr.</last_name>
      <email>e.d.kerver@olvg.nl</email>
    </contact>
    <investigator>
      <last_name>E.D. Kerver, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie West</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.C. Ogilvie, dr.</last_name>
      <email>a.ogilvie@slaz.nl</email>
    </contact>
    <investigator>
      <last_name>A.C. Ogilvie, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.M.W. Verheul, prof. dr.</last_name>
      <email>h.verheul@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>H.M.W. Verheul, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.C. Rietbroek, dr.</last_name>
      <email>rrietbroek@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>R.C. Rietbroek, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. de Klerk, dr.</last_name>
      <email>g.de.klerk@kg.nl</email>
    </contact>
    <investigator>
      <last_name>G. de Klerk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Hilversum</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.M.T. van der Velde, dr.</last_name>
      <email>avandervelden@tergooi.nl</email>
    </contact>
    <investigator>
      <last_name>A.M.T. van der Velde, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. de Valk, dr.</last_name>
      <email>bdevalk@spaarneziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B. de Valk, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D.J.A. Sonneveld, dr.</last_name>
      <email>d.j.a.sonneveld@westfriesgasthuis.nl</email>
    </contact>
    <investigator>
      <last_name>D.J.A. Sonneveld, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterlandziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.A.C Brakenhoff, dr.</last_name>
      <email>brakenhoff@wlz.nl</email>
    </contact>
    <investigator>
      <last_name>J.A.C. Brakenhoff, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medical Center</name>
      <address>
        <city>Zaandam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. van Bochove, dr.</last_name>
      <email>bochove.a@zaansmc.nl</email>
    </contact>
    <investigator>
      <last_name>A. van Bochove, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.S.L. Liem, dr</last_name>
      <email>m.s.l.liem@dz.nl</email>
    </contact>
    <investigator>
      <last_name>M.S.L. Liem, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.C.J.C. Legdeur, dr.</last_name>
      <email>m.legdeur@mst.nl</email>
    </contact>
    <investigator>
      <last_name>M.C.J.C. Legdeur, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Hoekstra</last_name>
      <email>r.hoekstra@zgt.nl</email>
    </contact>
    <investigator>
      <last_name>R. Hoekstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W.B. de Groot, dr.</last_name>
      <email>j.w.b.de.groot@isala.nl</email>
    </contact>
    <investigator>
      <last_name>J.W.B. de Groot, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.J. Rodenburg, dr.</last_name>
      <email>c.rodenburg@meandermc.nl</email>
    </contact>
    <investigator>
      <last_name>C.J. Rodenburg, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Los, dr.</last_name>
      <email>m.los@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>M. Los, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter ziekenhuis</name>
      <address>
        <city>Goes</city>
        <state>Zeeland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Van Halteren</last_name>
      <email>h.vanhalteren@adrz.nl</email>
    </contact>
    <investigator>
      <last_name>H. Van Halteren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda ziekenhuis</name>
      <address>
        <city>Hoogeveen</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Haasjes</last_name>
      <email>j.haasjes@treant.nl</email>
    </contact>
    <investigator>
      <last_name>J Haasjes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.M.E.M. Bos, dr.</last_name>
      <email>M.Bos@rdgg.nl</email>
    </contact>
    <investigator>
      <last_name>M.M.E.M. Bos, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.E.A. Portielje, dr.</last_name>
      <email>j.portielje@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>J.E.A. Portielje, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden, Westeinde</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.H. Helgason, dr.</last_name>
      <email>h.helgason@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>H.H. Helgason, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Trajkovic, Drs.</last_name>
      <email>m.vidakovic@asz.nl</email>
    </contact>
    <investigator>
      <last_name>M. Trajkovic, Drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.C. Tanis, dr.</last_name>
      <email>bea.tanis@ghz.nl</email>
    </contact>
    <investigator>
      <last_name>B.C. Tanis, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.W. Kapiteijn, dr.</last_name>
      <email>h.w.kapiteijn@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>H.W. Kapiteijn, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F.E. de Jongh, dr.</last_name>
      <email>fe.de.jongh@ikazia.nl</email>
    </contact>
    <investigator>
      <last_name>F.E. de Jongh, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Haberkorn, dr.</last_name>
      <email>haberkornb@maasstadziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B. Haberkorn, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.P. Hamberg, dr.</last_name>
      <email>p.hamberg@franciscus.nl</email>
    </contact>
    <investigator>
      <last_name>A.P. Hamberg, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscus Vlietland</name>
      <address>
        <city>Schiedam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.B. Ruit, dr.</last_name>
      <email>j.ruit@franciscus.nl</email>
    </contact>
    <investigator>
      <last_name>J.B. Ruit, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Koopman, dr.</last_name>
      <email>m.koopman-6@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>M. Koopman, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Treant zorggroep</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Z Erjavec</last_name>
      <email>z.erjavec@treant.nl</email>
    </contact>
    <investigator>
      <last_name>Z z.erjavec@treant.nl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.S. de Jong, dr.</last_name>
      <email>r.s.dejong@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>R.S. de Jong, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.A.P. Hospers, dr</last_name>
      <email>g.a.p.hospers@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>G.A.P. Hospers, dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Website Dutch Colorectal Cancer Group</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Anti-EGFR</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>R0 R1 liver resection</keyword>
  <keyword>Resectability of liver</keyword>
  <keyword>Liver expert panel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

